R. Laporte

发表

Mechanisms of smooth muscle contraction.

K. Morgan, A. Horowitz, C. B. Menice, 1996, Physiological reviews.

The Sarcoplasmic Reticulum Modulates Ca2+- Dependent Vasoconstriction

I. Laher, R. Laporte, 1994 .

Modulation of the effects of norepinephrine uptake inhibitors on the norepinephrine-induced contractile response of the porcine uterine artery during early pregnancy.

R. Laporte, L. Deroth, 1997, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.

New, potent, and selective peptidic oxytocin receptor agonists.

P. Rivière, R. Laporte, R. Galyean, 2014, Journal of medicinal chemistry.

Further evidence from an elastic artery that angiotensin II amplifies noradrenaline-induced contraction through activation of protein kinase C.

J. Bevan, I. Laher, D. Henrion, 1992, European journal of pharmacology.

Nonpeptide oxytocin agonists

A. Tartar, R. Laporte, G. R. Pitt, 2006 .

Sarcoplasmic reticulum and endothelium independently regulate venous smooth muscle [Ca2+]iand contraction.

I. Laher, R. Laporte, 1999, American journal of physiology. Heart and circulatory physiology.

Sarcoplasmic reticulum and endothelium independently regulate venous smooth muscle [Ca(2+)](i) and contraction.

I. Laher, R. Laporte, 1999, American Journal of Physiology.

Phorbol ester-induced potentiation of myogenic tone is not associated with increases in Ca2+ influx, myoplasmic free Ca2+ concentration, or 20-kDa myosin light chain phosphorylation.

I. Laher, R. Laporte, J. Haeberle, 1994, Journal of molecular and cellular cardiology.

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome

P. Rivière, D. Hargrove, Karthik Srinivasan, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.

P. Rivière, Yung-Chih Wang, J. J. Dwyer, 2016, Journal of medicinal chemistry.

Sarcoplasmic reticulum-sarcolemma interactions and vascular smooth muscle tone.

I. Laher, R. Laporte, 1997, Journal of vascular research.

Discovery of Potent, Selective, and Short-Acting Peptidic V2 Receptor Agonists.

P. Rivière, D. Hargrove, J. Kraus, 2019, Journal of medicinal chemistry.

Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial

M. Georgieff, P. Asfar, P. Radermacher, 2009, Critical care.

New, potent, selective, and short-acting peptidic V1a receptor agonists.

P. Rivière, R. Laporte, R. Galyean, 2011, Journal of medicinal chemistry.

Selepressin and Arginine Vasopressin Do Not Display Cardiovascular Risk in Atherosclerotic Rabbit

M. Henriksson, R. Laporte, R. Blakytny, 2016, PloS one.

Arginine vasopressin increases plasma levels of von Willebrand factor in sheep

P. Enkhbaatar, R. Laporte, S. Rehberg, 2009, Critical Care.

Vasopressin in vasodilatory shock: is the heart in danger?

M. Georgieff, P. Asfar, P. Radermacher, 2008, Critical care.

The Selective Vasopressin Type 1a Receptor Agonist Selepressin (FE 202158) Blocks Vascular Leak in Ovine Severe Sepsis*

Juanjuan Fan, L. Traber, D. Traber, 2014, Critical care medicine.

Pharmacological Characterization of FE 202158, a Novel, Potent, Selective, and Short-Acting Peptidic Vasopressin V1a Receptor Full Agonist for the Treatment of Vasodilatory Hypotension

P. Rivière, J. Dykert, R. Laporte, 2011, Journal of Pharmacology and Experimental Therapeutics.

Selective V1a receptor agonist FE 202158 reverses platelet-activating factor-induced hypotension, vascular leak, impaired tissue perfusion, and mortality in rats

D. Landry, R. Laporte, P. Rivière, 2008, Critical Care.

Pharmacological Modulation of Sarcoplasmic Reticulum Function in Smooth Muscle

I. Laher, R. Laporte, A. Hui, 2004, Pharmacological Reviews.

A role for MAP kinase in differentiated smooth muscle contraction evoked by α-adrenoceptor stimulation.

Chantal Dessy, C. Dessy, Inkyeom Kim, 1998, American journal of physiology. Cell physiology.

Isozyme‐specific inhibitors of protein kinase C translocation: effects on contractility of single permeabilized vascular muscle cells of the ferret

Inkyeom Kim, K. Morgan, M. Walsh, 1999, The Journal of physiology.

Effects of exercise on skeletal muscle and serum enzyme activities in pigs

R. Laporte, L. Deroth, F. Doizé, 2004, Veterinary Research Communications.

Synthesis and in vitro pharmacological profile of potent and selective peptidic V1a receptor agonists.

P. Rivière, R. Laporte, R. Galyean, 2009, Advances in experimental medicine and biology.

Angiotensin II amplifies arterial contractile response to norepinephrine without increasing Ca++ influx: role of protein kinase C.

J. Bevan, I. Laher, D. Henrion, 1992, The Journal of pharmacology and experimental therapeutics.

A Selective V1A Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock*

J. Vincent, F. Taccone, R. Laporte, 2015, Critical care medicine.

Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor*

L. Traber, D. Traber, P. Rivière, 2012, Critical care medicine.

Selective Partial Agonism of Vasopressin 1a Receptors In Vitro by OCE-205

E. Cable, R. Laporte, S. Bukofzer, 2023, Journal of Pharmacology and Pharmacotherapeutics.

A role for MAP kinase in differentiated smooth muscle contraction evoked by alpha-adrenoceptor stimulation.

C. Dessy, K. Morgan, R. Laporte, 1998, The American journal of physiology.